RGD Reference Report - Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease.

Authors: Nakamura, T  Ushiyama, C  Suzuki, S  Ebihara, I  Shimada, N  Koide, H 
Citation: Nakamura T, etal., Am J Nephrol. 2000 Jan-Feb;20(1):32-6.
RGD ID: 7207194
Pubmed: PMID:10644865   (View Abstract at PubMed)
DOI: DOI:13552   (Journal Full-text)

Several studies on polycystic kidney disease (PKD) have revealed a number of extracellular matrix (ECM) abnormalities, suggesting that an abnormal ECM plays a role in the development of tubular cysts. Cystic kidney tubules synthesize and secrete high levels of metalloproteinases (MMP), which may participate in the restructuring of the tubular basement membrane. The aim of the present study was to determine whether serum MMP-1, tissue inhibitor of metalloproteinase (TIMP)-1, and type IV collagen levels, and plasma MMP-9 levels were altered in patients with PKD. Sixteen patients with autosomal dominant polycystic kidney disease, and 20 healthy controls were included in this study. Specific enzyme immunoassays were used to measure MMP-1, MMP-9, TIMP-1, and type IV collagen levels. Serum MMP-1 (14.8 +/- 3.6 ng/ml), TIMP-1 (288.6 +/- 48.6 ng/ml), and type IV collagen (192.6 +/- 38.8 ng/ml) concentrations, and plasma MMP-9 (90.2 +/- 26.8 ng/ml) concentrations in patients with PKD were significantly higher than those in healthy controls (MMP-1; 6.6 +/- 0.9 ng/ml, p < 0.01, MMP-9; 36.4 +/- 12.2 ng/ml, p < 0.01, TIMP-1; 164.6 +/- 22.8 ng/ml, p < 0.01, and type IV collagen; 86.6 +/- 14.2 ng/ml, p < 0.001). The present results suggest that ECM abnormalities associated with cystic kidney may result from aberrant degradation as well as from abnormal synthesis of ECM components.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
autosomal dominant polycystic kidney disease  IEP 7207194protein:increased expression:serum (human)RGD 
autosomal dominant polycystic kidney disease  IEP 7207194protein:increased expression:plasma (human)RGD 
autosomal dominant polycystic kidney disease  ISOMMP1 (Homo sapiens)7207194; 7207194protein:increased expression:serum (human)RGD 
autosomal dominant polycystic kidney disease  ISOMMP9 (Homo sapiens)7207194; 7207194protein:increased expression:plasma (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Mmp1  (matrix metallopeptidase 1)
Mmp9  (matrix metallopeptidase 9)

Genes (Mus musculus)
Mmp1a  (matrix metallopeptidase 1a (interstitial collagenase))
Mmp9  (matrix metallopeptidase 9)

Genes (Homo sapiens)
MMP1  (matrix metallopeptidase 1)
MMP9  (matrix metallopeptidase 9)


Additional Information